{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:29:37Z","timestamp":1791836977523,"version":"4.3.4"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T00:00:00Z","timestamp":1654214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Three- and five-year progression-free survival (PFS) for low-risk meningioma managed with surgery and observation reportedly exceeds 90%. Herewith we summarize outcomes for low-risk meningioma patients enrolled on NRG\/RTOG 0539.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase II trial allocated patients to one of three groups per World Health Organization grade, recurrence status, and resection extent. Low-risk patients had either gross total (GTR) or subtotal resection (STR) for a newly diagnosed grade 1 meningioma and were observed after surgery. The primary endpoint was 3-year PFS. Adverse events (AEs) were scored using Common Terminology Criteria for Adverse Events (CTCAE) version 3.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 60 evaluable patients, the median follow-up was 9.1 years. The 3-, 5-, and 10-year rates were 91.4% (95% CI, 84.2 to 98.6), 89.4% (95% CI, 81.3 to 97.5), 85.0% (95% CI, 75.3 to 94.7) for PFS and 98.3% (95% CI, 94.9 to 100), 98.3%, (95% CI, 94.9 to 100), 93.8% (95% CI, 87.0 to 100) for overall survival (OS), respectively. With centrally confirmed GTR, 3\/5\/10y PFS and OS rates were 94.3\/94.3\/87.6% and 97.1\/97.1\/90.4%. With STR, 3\/5\/10y PFS rates were 83.1\/72.7\/72.7% and 10y OS 100%. Five patients reported one grade 3, four grade 2, and five grade 1 AEs. There were no grade 4 or 5 AEs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>These results prospectively validate high PFS and OS for low-risk meningioma managed surgically but raise questions regarding optimal management following STR, a subcohort that could potentially benefit from adjuvant therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noac137","type":"journal-article","created":{"date-parts":[[2022,6,3]],"date-time":"2022-06-03T14:24:59Z","timestamp":1654266299000},"page":"137-145","source":"Crossref","is-referenced-by-count":48,"title":["Low-risk meningioma: Initial outcomes from NRG Oncology\/RTOG 0539"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-8838","authenticated-orcid":false,"given":"C Leland","family":"Rogers","sequence":"first","affiliation":[{"name":"GammaWest Cancer Services , Salt Lake City, Utah , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L","family":"Pugh","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A","family":"Vogelbaum","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Neuosurgery , Tampa, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arie","family":"Perry","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Neuropathology , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn S","family":"Ashby","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute , Neurology, Phoenix, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jignesh M","family":"Modi","sequence":"additional","affiliation":[{"name":"MidState Medical Center, Radiology , Meriden, Connecticut , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony M","family":"Alleman","sequence":"additional","affiliation":[{"name":"University of Oklahoma, Radiology , Oklahoma City, Oklahoma , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor J","family":"Barani","sequence":"additional","affiliation":[{"name":"Barrow Neurological Institute, Radiation Oncology , Phoenix, Arizona , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Braunstein","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Radiation Oncology , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A","family":"Bovi","sequence":"additional","affiliation":[{"name":"Medical College of Wisconsin, Radiation Oncology , Milwaukee, Wisconsin , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"de Groot","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, Neuro Oncology , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony C","family":"Whitton","sequence":"additional","affiliation":[{"name":"Juravinski Cancer Centre, Radiation Oncology , Hamilton, Ontario , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott M","family":"Lindhorst","sequence":"additional","affiliation":[{"name":"Medical University of South Carolina, Neuro Oncology , Charleston, South Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimisha","family":"Deb","sequence":"additional","affiliation":[{"name":"St. Luke\u2019s Hospital-Anderson Campus Cancer Center , Easton, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis C","family":"Shrieve","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute, Radiation Oncology, University of Utah , Salt Lake City, Utah , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Kuo","family":"Shu","sequence":"additional","affiliation":[{"name":"Winship Cancer Institute at Emory University, Radiation Oncology , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Bloom","sequence":"additional","affiliation":[{"name":"Northwell Health, Radiation Oncology , New Hyde Park, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Machtay","sequence":"additional","affiliation":[{"name":"Penn State Cancer Institute, Radiation Oncology , Hershey, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark V","family":"Mishra","sequence":"additional","affiliation":[{"name":"University of Maryland, Radiation Oncology, Baltimore , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford G","family":"Robinson","sequence":"additional","affiliation":[{"name":"Washington University, Radiation Oncology , St. Louis, St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhee","family":"Won","sequence":"additional","affiliation":[{"name":"NRG Oncology Statistics and Data Management Center , Philadelphia, Pennsylvania , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minesh P","family":"Mehta","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida , Miami, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,3]]},"reference":[{"issue":"Suppl 4)","key":"2023010802394232000_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nou223","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007\u20132011","volume":"16","author":"Ostrom","year":"2014","journal-title":"Neuro Oncol."},{"issue":"6","key":"2023010802394232000_CIT0002","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1227\/01.NEU.0000188281.91351.B9","article-title":"Epidemiology of intracranial meningioma","volume":"57","author":"Claus","year":"2005","journal-title":"Neurosurgery."},{"issue":"3","key":"2023010802394232000_CIT0003","first-page":"231","article-title":"The histopathological spectrum of human meningiomas","volume":"5","author":"Backer-Gr\u00f8ndahl","year":"2012","journal-title":"Int J Clin Exp Pathol."},{"issue":"1","key":"2023010802394232000_CIT0004","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3171\/2014.7.JNS131644","article-title":"Meningiomas: knowledge base, treatment outcomes, and uncertainties: a RANO review","volume":"122","author":"Rogers","year":"2015","journal-title":"J Neurosurg."},{"issue":"1","key":"2023010802394232000_CIT0005","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3171\/2016.11.JNS161170","article-title":"Intermediate-risk meningioma: initial outcomes from NRG Oncology\/RTOG-0539","volume":"129","author":"Rogers","year":"2018","journal-title":"J Neurosurg."},{"issue":"4","key":"2023010802394232000_CIT0006","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.ijrobp.2019.11.028","article-title":"High-risk meningioma: initial outcomes from NRG Oncology\/RTOG 0539","volume":"106","author":"Rogers","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"1","key":"2023010802394232000_CIT0007","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1136\/jnnp.20.1.22","article-title":"The recurrence of intracranial meningiomas after surgical treatment","volume":"20","author":"Simpson","year":"1957","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2023010802394232000_CIT0008","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/neuonc\/nov247","article-title":"Pathology concordance levels for meningioma classification and grading in RTOG trial 0539","volume":"18","author":"Rogers","year":"2015","journal-title":"Neuro Oncol."},{"issue":"3","key":"2023010802394232000_CIT0009","doi-asserted-by":"crossref","first-page":"276","DOI":"10.11613\/BM.2012.031","article-title":"Interrater reliability: the kappa statistic","volume":"22","author":"McHugh","year":"2012","journal-title":"Biochem Med (Zagreb)"},{"issue":"8","key":"2023010802394232000_CIT0010","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"issue":"5","key":"2023010802394232000_CIT0011","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.ijrobp.2010.07.039","article-title":"Improved correlation of the neuropathologic classification according to adapted World Health Organization classification and outcome after radiotherapy in patients with atypical and anaplastic meningiomas","volume":"81","author":"Combs","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2023010802394232000_CIT0012","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/neuonc\/not325","article-title":"Proposal for a new risk stratification classification for meningioma based on patient age, WHO tumor grade, size, localization, and karyotype","volume":"16","author":"Domingues","year":"2014","journal-title":"Neuro Oncol."},{"key":"2023010802394232000_CIT0013","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/bpa.12174","article-title":"Mitotic index is an independent predictor of recurrence-free survival in meningioma","volume":"25","author":"Olar","year":"2015","journal-title":"Brain Pathol."},{"issue":"2","key":"2023010802394232000_CIT0014","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0360-3016(97)00317-9","article-title":"Benign meningiomas: primary treatment selection affects survival","volume":"39","author":"Condra","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2023010802394232000_CIT0015","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3171\/2012.3.JNS111945","article-title":"Significance of Simpson grading system in modern meningioma surgery: integration of the grade with MIB-1 labeling index as a key to predict the recurrence of WHO Grade I meningiomas","volume":"117","author":"Oya","year":"2012","journal-title":"J Neurosurg."},{"issue":"5","key":"2023010802394232000_CIT0016","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3171\/2010.3.JNS091971","article-title":"The relevance of Simpson Grade I and II resection in modern neurosurgical treatment of World Health Organization Grade I meningiomas","volume":"113","author":"Sughrue","year":"2010","journal-title":"J Neurosurg."},{"issue":"6","key":"2023010802394232000_CIT0017","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3171\/2012.9.JNS12294","article-title":"Surgery for convexity meningioma: Simpson Grade I resection as the goal: clinical article","volume":"117","author":"Hasseleid","year":"2012","journal-title":"J Neurosurg."},{"issue":"6","key":"2023010802394232000_CIT0018","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.3171\/2020.4.JNS20412","article-title":"Risk of tumor recurrence in intracranial meningiomas: comparative analyses of the predictive value of the postoperative tumor volume and the Simpson classification","volume":"134","author":"Spille","year":"2020","journal-title":"J Neurosurg."},{"issue":"1","key":"2023010802394232000_CIT0019","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3171\/jns.1985.62.1.0018","article-title":"Meningioma: analysis of recurrence and progression following neurosurgical resection","volume":"62","author":"Mirimanoff","year":"1985","journal-title":"J Neurosurg."},{"issue":"10","key":"2023010802394232000_CIT0020","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4065\/73.10.936","article-title":"Primarily resected meningiomas: outcome and prognostic factors in 581 Mayo Clinic patients, 1978 through 1988","volume":"73","author":"Stafford","year":"1998","journal-title":"Mayo Clin Proc."},{"issue":"5","key":"2023010802394232000_CIT0021","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.3171\/2010.12.JNS101623","article-title":"The natural history of intracranial meningiomas","volume":"114","author":"Oya","year":"2011","journal-title":"J Neurosurg."},{"key":"2023010802394232000_CIT0022","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.wneu.2016.02.066","article-title":"Surgical outcomes and predictors of recurrence in elderly patients with meningiomas","volume":"90","author":"Bir","year":"2016","journal-title":"World Neurosurg."},{"issue":"5","key":"2023010802394232000_CIT0023","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.ijrobp.2004.05.073","article-title":"Factors predicting local tumor control after gamma knife stereotactic radiosurgery for benign intracranial meningiomas","volume":"60","author":"Dibiase","year":"2004","journal-title":"Int Radiat Oncol Biol Phys"},{"issue":"6","key":"2023010802394232000_CIT0024","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1212\/01.WNL.0000138569.45818.50","article-title":"Natural history of conservatively treated meningiomas","volume":"63","author":"Herscovici","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"2023010802394232000_CIT0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/MAO.0000000000001260","article-title":"The natural history of petroclival meningiomas: a volumetric study","volume":"38","author":"Hunter","year":"2017","journal-title":"Otol Neurotol."},{"issue":"2","key":"2023010802394232000_CIT0026","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-019-03104-3","article-title":"Incidental intracranial meningiomas: a systematic review and metaanalysis of prognostic factors and outcomes","volume":"142","author":"Islim","year":"2019","journal-title":"J Neuro-Oncol."},{"issue":"2","key":"2023010802394232000_CIT0027","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00172765","article-title":"The role of radiotherapy in the treatment of subtotally resected benign meningiomas","volume":"13","author":"Miralbell","year":"1992","journal-title":"J Neurooncol."},{"issue":"1","key":"2023010802394232000_CIT0028","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.radonc.2004.01.006","article-title":"Radiotherapy after surgery for benign cerebral meningioma","volume":"71","author":"Soyuer","year":"2004","journal-title":"Radiother Oncol."},{"issue":"7","key":"2023010802394232000_CIT0029","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1093\/neuonc\/noz061","article-title":"DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management","volume":"21","author":"Nassiri","year":"2019","journal-title":"Neuro Oncol."},{"key":"2023010802394232000_CIT0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40478-020-00952-3","article-title":"DNA methylation profiling demonstrates superior diagnostic classification to RNA-sequencing in a case of metastatic meningioma","volume":"8","author":"Vasudevan","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"5","key":"2023010802394232000_CIT0031","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/S1470-2045(17)30155-9","article-title":"DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis","volume":"18","author":"Sahm","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"2023010802394232000_CIT0032","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1093\/neuonc\/noab118","article-title":"Activity of PD-1 blockade with nivolumab among patients with recurrent atypical\/anaplastic meningioma: phase II trial results","volume":"24","author":"Bi","year":"2022","journal-title":"Neuro Oncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noac137\/44382517\/noac137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/1\/137\/48496890\/noac137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/25\/1\/137\/48496890\/noac137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T02:42:44Z","timestamp":1673145764000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/25\/1\/137\/6601387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,3]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,6,3]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noac137","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,6,3]]}}}